Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is thought to exert its effects by enhancing the activity of the neurotransmitter gamma-aminobutyric acid (GABA).
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* Initiate at 5 mg twice daily.
* Increase dose by 5-10 mg per day every 7 days to a target maintenance dose of 0.5-1 mg/kg/day, divided into two daily doses.
* Maximum daily dose: 20 mg twice daily (40 mg/day) for adults weighing over 30 kg.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* **2 to <10 years of age OR < 30 kg:**
* Initiate at 2.5 mg once daily.
* Increase dose by 2.5-5 mg per day every 7 days to a target maintenance dose of 0.5-1 mg/kg/day, divided into two daily doses.
* Maximum daily dose: 10 mg twice daily (20 mg/day).
* **10 years of age and older OR ≥ 30 kg:**
* Dosing is the same as adult dosing.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosage adjustments are recommended, but initiation at the lower end of the dosing range and slow titration may be prudent.
* **Renal Impairment:** Use with caution. No specific dosage adjustments are recommended, but initiation at the lower end of the dosing range and slow titration may be prudent.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
* Severe respiratory impairment.
* Acute narrow-angle glaucoma.
## Adverse Effects
Common adverse effects include: somnolence, decreased appetite, vomiting, constipation, irritability, aggression, upper respiratory tract infection, and pneumonia. Serious adverse effects include: severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms, and suicidal behavior or ideation.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation and respiratory depression.
* **CYP3A4 Inhibitors (e.g., ketoconazole, fluconazole):** May increase clobazam levels.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam levels.
* **CNS Stimulants (e.g., amphetamines):** May antagonize the sedative effects of clobazam.
* **Valproic Acid:** Co-administration may increase valproic acid levels.
## Monitoring
* Monitor for somnolence, behavioral changes, and signs of respiratory depression.
* Monitor for signs of withdrawal upon discontinuation.
* Monitor for efficacy in seizure control.
* Monitor for severe skin reactions.
## Clinical Pearls
* Clobazam is generally used as adjunctive therapy for LGS.
* Due to the risk of serious skin reactions, patients should be advised to discontinue clobazam and seek immediate medical attention if they develop a rash.
* Gradual tapering of the dose is recommended when discontinuing clobazam to avoid withdrawal symptoms.
* Patients should be advised against operating heavy machinery or driving until they know how clobazam affects them.
***
**Disclaimer:** This information is intended for clinical use and does not replace the need to consult the official prescribing information or other authoritative sources for complete and current drug information. Always verify current prescribing information before making clinical decisions.
